Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects three bowel cancer drugs

The National Institute for Health and Clinical Excellence (NICE) has decided to not recommend three metastatic colorectal cancer drugs as they are not deemed cost effective

The National Institute for Health and Clinical Excellence (NICE) has rejected three drugs for the treatment of metastatic colorectal cancer, as they do not represent value for money.

NICE decided not to recommend Roche's Avastin, Merck KGaA's Erbitux and Amgen's Vectibix, as the high cost of the drugs could not be justified. The agency said that no convincing data was presented to demonstrate the extension of life for a patient with the disease.

NICE has currently recommended six treatments for the various stages of colorectal cancer, and commented that it was “disappointed not to be able to recommend” the three drugs.

Around 20-55 per cent of people with colorectal cancer have metastatic disease by the time of diagnosis.

The companies have been allowed to submit further comments on the committee's interpretation of their products, or consider reducing their prices.

5th September 2011

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics